Neumora Therapeutics, Inc. (NMRA)
0.4739
-0.01
(-1.23%)
USD |
NASDAQ |
Oct 09, 16:00
0.4739
0.00 (0.00%)
After-Hours: 20:00
Neumora Therapeutics Debt to Equity Ratio : 1.196 for June 30, 2026
Debt to Equity Ratio Chart
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| June 30, 2026 | 1.196 |
| March 31, 2026 | 0.7551 |
| December 31, 2025 | 0.5296 |
| September 30, 2025 | 0.152 |
| June 30, 2025 | 0.1091 |
| March 31, 2025 | 0.0041 |
| December 31, 2024 | 0.0065 |
| September 30, 2024 | 0.0086 |
| June 30, 2024 | 0.0095 |
| Date | Value |
|---|---|
| March 31, 2024 | 0.0104 |
| December 31, 2023 | 0.0112 |
| September 30, 2023 | 0.012 |
| June 30, 2023 | 0.0207 |
| March 31, 2023 | 0.0209 |
| December 31, 2022 | 0.0213 |
| September 30, 2022 | |
| June 30, 2022 | |
| March 31, 2022 | 0.0049 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Debt to Equity Ratio Benchmarks
| BioAge Labs, Inc. | 0.0076 |
| ANI Pharmaceuticals, Inc. | 1.022 |
| Corcept Therapeutics, Inc. | 0.0133 |
| Veru, Inc. | 0.0945 |
| Johnson & Johnson | 0.5771 |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 125.25M |
| Total Liabilities (Quarterly) | 80.73M |
| Shareholders Equity (Quarterly) | 44.52M |
| Current Ratio | 4.496 |
| Net Debt Paydown Yield | -3.29% |